FMTX Key Statistics, Chart & Performance
The current stock price of FMTX is 20.01 USD. In the past month the price increased by 0.2%. In the past year, price increased by 10.61%.
FMTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FMTX. When comparing the yearly performance of all stocks, FMTX is one of the better performing stocks in the market, outperforming 99.11% of all stocks.
FMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FMTX. FMTX has a great financial health rating, but its profitability evaluates not so good.
FMTX Financial Highlights
Over the last trailing twelve months FMTX reported a non-GAAP Earnings per Share(EPS) of -4. The EPS decreased by -32.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.02% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
FMTX Forecast & Estimates
12 analysts have analysed FMTX and the average price target is 21.01 USD. This implies a price increase of 5.01% is expected in the next year compared to the current price of 20.01.
FMTX Ownership
About FMTX
Company Profile
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
Company Info
FORMA THERAPEUTICS HOLDINGS
300 North Beacon Street, Suite 501
Watertown MASSACHUSETTS 02472 US
CEO: Frank D. Lee
Employees: 189
Phone: 16176791970.0
FORMA THERAPEUTICS HOLDINGS / FMTX FAQ
Can you describe the business of FORMA THERAPEUTICS HOLDINGS?
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
What is the stock price of FORMA THERAPEUTICS HOLDINGS today?
The current stock price of FMTX is 20.01 USD. The price increased by 0.15% in the last trading session.
Does FMTX stock pay dividends?
FMTX does not pay a dividend.
What is the ChartMill rating of FORMA THERAPEUTICS HOLDINGS stock?
FMTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about FORMA THERAPEUTICS HOLDINGS (FMTX) stock?
12 analysts have analysed FMTX and the average price target is 21.01 USD. This implies a price increase of 5.01% is expected in the next year compared to the current price of 20.01.
Can you provide the number of employees for FORMA THERAPEUTICS HOLDINGS?
FORMA THERAPEUTICS HOLDINGS (FMTX) currently has 189 employees.
Can you provide the ownership details for FMTX stock?
You can find the ownership structure of FORMA THERAPEUTICS HOLDINGS (FMTX) on the Ownership tab.